Clinical Research Directory
Browse clinical research sites, groups, and studies.
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
Sponsor: Hospital das Clínicas de Ribeirão Preto
Summary
The study is studying the joint contribution and interactions of germline variants and somatic mutations and their impact on Renal Cell Carcinoma (RCC) development and treatment (immunotherapy).
Official title: CLARA: Characterization of Somatic and Germline Mechanisms That Impact the Immunotherapy Treatment and Prognosis of Patients With Renal Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2022-01-18
Completion Date
2026-11-30
Last Updated
2024-07-03
Healthy Volunteers
No
Conditions
Interventions
Nivolumab
Nivolumab is called an anti-PD-1 (Programmed Cell Death Ligand 1) or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
Ipilimumab
Ipilimumab is called an anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
Locations (1)
Hospital das Clínicas da Faculdade de Medicina de Ribeirao Preto - USP
Ribeirão Preto, São Paulo, Brazil